vs

Side-by-side financial comparison of Phreesia, Inc. (PHR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $120.3M, roughly 1.7× Phreesia, Inc.). Phreesia, Inc. runs the higher net margin — 3.5% vs -62.0%, a 65.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 12.7%). Phreesia, Inc. produced more free cash flow last quarter ($12.2M vs $-100.8M).

Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PHR vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.7× larger
RARE
$207.3M
$120.3M
PHR
Growing faster (revenue YoY)
RARE
RARE
+13.2% gap
RARE
25.9%
12.7%
PHR
Higher net margin
PHR
PHR
65.6% more per $
PHR
3.5%
-62.0%
RARE
More free cash flow
PHR
PHR
$113.0M more FCF
PHR
$12.2M
$-100.8M
RARE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
PHR
PHR
RARE
RARE
Revenue
$120.3M
$207.3M
Net Profit
$4.3M
$-128.6M
Gross Margin
Operating Margin
3.1%
-54.7%
Net Margin
3.5%
-62.0%
Revenue YoY
12.7%
25.9%
Net Profit YoY
129.7%
3.5%
EPS (diluted)
$0.07
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHR
PHR
RARE
RARE
Q4 25
$120.3M
$207.3M
Q3 25
$117.3M
$159.9M
Q2 25
$115.9M
$166.5M
Q1 25
$139.3M
Q4 24
$164.6M
Q3 24
$139.5M
Q2 24
$147.0M
Q1 24
$108.8M
Net Profit
PHR
PHR
RARE
RARE
Q4 25
$4.3M
$-128.6M
Q3 25
$654.0K
$-180.4M
Q2 25
$-3.9M
$-115.0M
Q1 25
$-151.1M
Q4 24
$-133.2M
Q3 24
$-133.5M
Q2 24
$-131.6M
Q1 24
$-170.7M
Operating Margin
PHR
PHR
RARE
RARE
Q4 25
3.1%
-54.7%
Q3 25
-1.3%
-106.9%
Q2 25
-2.8%
-64.8%
Q1 25
-102.6%
Q4 24
-74.3%
Q3 24
-94.6%
Q2 24
-79.1%
Q1 24
-151.9%
Net Margin
PHR
PHR
RARE
RARE
Q4 25
3.5%
-62.0%
Q3 25
0.6%
-112.8%
Q2 25
-3.4%
-69.0%
Q1 25
-108.5%
Q4 24
-80.9%
Q3 24
-95.7%
Q2 24
-89.5%
Q1 24
-156.8%
EPS (diluted)
PHR
PHR
RARE
RARE
Q4 25
$0.07
$-1.28
Q3 25
$0.01
$-1.81
Q2 25
$-0.07
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHR
PHR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$106.4M
$421.0M
Total DebtLower is stronger
$3.4M
Stockholders' EquityBook value
$320.3M
$-80.0M
Total Assets
$423.5M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHR
PHR
RARE
RARE
Q4 25
$106.4M
$421.0M
Q3 25
$98.3M
$202.5M
Q2 25
$90.9M
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Q1 24
$112.3M
Total Debt
PHR
PHR
RARE
RARE
Q4 25
$3.4M
Q3 25
$4.6M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PHR
PHR
RARE
RARE
Q4 25
$320.3M
$-80.0M
Q3 25
$298.0M
$9.2M
Q2 25
$282.2M
$151.3M
Q1 25
$144.2M
Q4 24
$255.0M
Q3 24
$346.8M
Q2 24
$432.4M
Q1 24
$140.3M
Total Assets
PHR
PHR
RARE
RARE
Q4 25
$423.5M
$1.5B
Q3 25
$408.6M
$1.2B
Q2 25
$400.4M
$1.3B
Q1 25
$1.3B
Q4 24
$1.5B
Q3 24
$1.5B
Q2 24
$1.6B
Q1 24
$1.3B
Debt / Equity
PHR
PHR
RARE
RARE
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHR
PHR
RARE
RARE
Operating Cash FlowLast quarter
$15.5M
$-99.8M
Free Cash FlowOCF − Capex
$12.2M
$-100.8M
FCF MarginFCF / Revenue
10.1%
-48.6%
Capex IntensityCapex / Revenue
2.7%
0.5%
Cash ConversionOCF / Net Profit
3.62×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHR
PHR
RARE
RARE
Q4 25
$15.5M
$-99.8M
Q3 25
$14.8M
$-91.4M
Q2 25
$14.8M
$-108.3M
Q1 25
$-166.5M
Q4 24
$-79.3M
Q3 24
$-67.0M
Q2 24
$-77.0M
Q1 24
$-190.7M
Free Cash Flow
PHR
PHR
RARE
RARE
Q4 25
$12.2M
$-100.8M
Q3 25
$13.1M
$-92.7M
Q2 25
$11.3M
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
PHR
PHR
RARE
RARE
Q4 25
10.1%
-48.6%
Q3 25
11.1%
-58.0%
Q2 25
9.8%
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
PHR
PHR
RARE
RARE
Q4 25
2.7%
0.5%
Q3 25
1.5%
0.8%
Q2 25
3.0%
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
PHR
PHR
RARE
RARE
Q4 25
3.62×
Q3 25
22.68×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHR
PHR

Subscription And Services$55.5M46%
Network Solutions$37.4M31%
Payment Processing Fees$27.4M23%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons